We propose that inactivation of E-cadherin, a lobular histology, and cytosolic Id2, should be considered as criteria to include ERNEG and HER2POS ILC patients for clinical CDK4/6 breast cancer intervention trials. The gene discussed is ID2; the disease is breast carcinoma.